Study of IFX-1 to Replace Steroids in Patients With Granulomatosis With Polyangiitis and Microscopic Polyangiitis. (IXchange)

• Sponsor: InflaRx GmbH
• Collaborator: IQVIA
• Information provided by (Responsible Party): InflaRx GmbH

Study Description

Brief Summary:

The purpose of the study is to evaluate the efficacy of IFX-1 treatment as replacement for glucocorticoid (GC) therapy in subjects with GPA and MPA.

Condition or disease	Intervention/treatment	Phase
Polyangiitis, Granulomatosis With	Drug: IFX-1; Drug: Placebo-IFX-1; Drug: Glucocorticoid (GC); Drug: Placebo-Glucocorticoid (Placebo-GC)	Phase 2

Detailed Description:

AAV is a group of potentially life-threatening autoimmune diseases. Preclinical data demonstrate that primed neutrophils are activated by ANCA and generate C5a that engages C5a receptors on neutrophils. Patients with ANCA-related disease have elevated plasma and urine levels of C5a in active disease but not in remission. IFX-1 is as a monoclonal antibody specifically binding to the soluble human complement split product C5a, which results in nearly complete blockade of C5a induced biological effects. Therefore, IFX-1 may be effective in the treatment of subjects with AAV.

In this Phase II study of 20 to 81 subjects with GPA or MPA, IFX-1 will be administered in combination with reduced dose glucocorticoids or a placebo glucocorticoid compared with standard dose glucocorticoids.

Study Design

Layout table for study information

Study Type :	Interventional (Clinical Trial)
Estimated Enrollment :	81 participants
Allocation:	Randomized
Intervention Model:	Parallel Assignment
Masking:	Double (Participant, Investigator)
Primary Purpose:	Treatment
Official Title:	A Randomized, Double-blind, Double-dummy, Active-controlled, Multicenter, 2-part Phase II Study on Replacement of Steroids by IFX-1 in Active Granulomatosis With Polyangiitis (GPA) and Microscopic Polyangiitis (MPA)
Actual Study Start Date :	March 22, 2019
Estimated Primary Completion Date :	March 2021
Estimated Study Completion Date :	July 2021

Arms and Interventions

Arm	Intervention/treatment
Experimental: Group A Experimental + active comparator; IFX-1 + reduced dose GC	Drug: IFX-1; intravenously administered; Other Name: CaCP29; Drug: Glucocorticoid (GC); orally administered; Other Name: Prednisone
Active Comparator: Group B Placebo + active comparator; Placebo-IFX-1 + standard dose GC	Drug: Placebo-IFX-1; intravenously administered; Other Name: Placebo; Drug: Glucocorticoid (GC); orally administered; Other Name: Prednisone
Placebo Comparator: Group C Experimental + placebo comparator; IFX-1 + Placebo-GC	Drug: IFX-1; intravenously administered; Other Name: CaCP29; Drug: Placebo-Glucocorticoid (Placebo-GC); orally administered; Other Name: Placebo

Outcome Measures

Primary Outcome Measures :

1. Proportion of subjects achieving clinical response (reduction in Birmingham Vasculitis Activity Score [BVAS] of ≥50% compared to baseline and no worsening in any body system) [ Time Frame: Week 16 ]
   Efficacy Endpoint based on clinical response evaluated through BVAS.

Secondary Outcome Measures :

1. Treatment-emergent adverse events (TEAE) [ Time Frame: Week 24 ]
   Safety endpoint: Number and percentage of subjects who had a TEAE.
2. Serious adverse events (SAEs) [ Time Frame: Week 24 ]
   Safety endpoint: Number and percentage of subjects with SAEs
3. Adverse Events of Special Interest (AESIs) [ Time Frame: Week 24 ]
   Safety endpoint: Number and percentage of subjects with AESIs
4. Glucocorticoid (GC)-induced toxicity of standard-dose GC and reduced-dose GC with IFX-1 treatment [ Time Frame: Week 24 ]
   Safety Endpoint: Glucocorticoid-induced toxicity as measured by the Glucocorticoid Toxicity Index
5. Pharmacokinetic and pharmacodynamic modelling of IFX-1 treatment [ Time Frame: Week 24 ]
   Plasma concentration of IFX-1

Eligibility Criteria

Layout table for eligibility information

Ages Eligible for Study:	18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

• Diagnosis of GPA or MPA
• Have ≥ 1 "major" item, or ≥ 3 other items, or ≥ 2 renal items on the Birmingham Vasculitis Activity Score Version 3 (BVASv3).
• Newly diagnosed or relapsed GPA or MPA that requires treatment with CYC or RTX plus GCs.
• Glomerular filtration rate ≥ 20 mL/min/1.73 m².

Exclusion Criteria:

• Any other multi-system autoimmune disease
• Require mechanical ventilation at screening.
• Known hypersensitivity to any investigational medicinal product
• Rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption.
• Have required management of infections within 30 days of screening.
• Current and/or history (within the previous 5 years) of drug and/or alcohol abuse and/or dependence.
• Hepatitis B virus, hepatitis C virus, or human immunodeficiency virus (HIV)
• Abnormal laboratory findings at screening
• Current or history of malignancy, lymphoproliferative, or myeloproliferative disorder
• Received CYC or RTX within 12 weeks before screening;
• Received > 3 g cumulative intravenous GCs within 4 weeks before screening.
• Received an oral daily dose of a GC of > 10 mg prednisone-equivalent for more than 6 weeks continuously prior to screening.
• Received a live vaccination within 4 weeks before screening
• Either active or latent tuberculosis treatment is ongoing.
• Pregnant or lactating.
• Abnormal electrocardiogram.
• Female subjects of childbearing potential unwilling or unable to use a highly effective method of contraception
• Participation in an investigational clinical study during the 12 weeks before screening.
• Male subjects with female partners of childbearing potential unwilling to use contraception

Contacts and Locations

Contacts

Layout table for location contacts

Contact: Othmar Zenker, MD	+49 3641 508193	info@inflarx.de
Contact: Zenker		info@inflarx.de

Locations

Layout table for location information

Czechia
Czech Republic	Recruiting
Hradec Králové, Czechia
Czech Republic	Recruiting
Prague, Czechia
Czech Republic	Recruiting
Praha, Czechia
France
France	Recruiting
Angers, France
France	Recruiting
Brest, France
France	Recruiting
Paris, France
Germany
Germany	Recruiting
Kirchheim unter Teck, Germany
Italy
Italy	Recruiting
Milano, Italy
Netherlands
Netherlands	Recruiting
Maastricht, Netherlands
Netherlands	Recruiting
Rotterdam, Netherlands
Spain
Spain	Recruiting
Alcorcón, Spain
Barcelona	Recruiting
Barcelona, Spain
Spain	Recruiting
Barcelona, Spain
Sevilla	Recruiting
Sevilla, Spain
Spain 2	Recruiting
Sevilla, Spain
Spain	Recruiting
Sevilla, Spain
Sweden
Sweden	Recruiting
Göteborg, Sweden
Sweden	Recruiting
Stockholm, Sweden

Sponsors and Collaborators

InflaRx GmbH

IQVIA

Investigators

Layout table for investigator information

Study Director:	Othmar Zenker, MD	InflaRx GmbH

More Information

Layout table for additonal information

Responsible Party:	InflaRx GmbH
ClinicalTrials.gov Identifier:	NCT03895801 History of Changes
Other Study ID Numbers:	IFX-1-P2.5
First Posted:	March 29, 2019
Last Update Posted:	May 9, 2019
Last Verified:	May 2019

Layout table for additional information

Studies a U.S. FDA-regulated Drug Product:		Yes
Studies a U.S. FDA-regulated Device Product:		No

Keywords provided by InflaRx GmbH:

granulomatosis; polyangiitis; corticosteroid; replacement; glucocorticoid

Additional relevant MeSH terms:

Layout table for MeSH terms

Systemic Vasculitis; Granulomatosis with Polyangiitis; Microscopic Polyangiitis; Vasculitis; Vascular Diseases; Cardiovascular Diseases; Lung Diseases, Interstitial; Lung Diseases; Respiratory Tract Diseases; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Autoimmune Diseases	Immune System Diseases; Cerebral Small Vessel Diseases; Cerebrovascular Disorders; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Glucocorticoids; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Physiological Effects of Drugs